Register
Community
Physicians
Editors
Experts
Code of conduct
Blog
Terms of Use
Privacy Policy
Sitemap
Company
About
Publications
Press
Careers
Programs
Journal Club
Targeted Topic
Clinical Trial
Tumor Board
Contact Us
Sign in
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Renal Cell Carcinoma
Do you routinely obtain next generation sequencing for patients with metastatic renal cell carcinoma and if so, what is your approach to incorporating these results into treatment decision making?
Related Questions
How do you reconcile the different trial results of KEYNOTE 574 and IMmotion010 for adjuvant checkpoint inhibitor use in RCC?
How do you manage hyponatremia in patients with renal cell carcinoma on cabozantanib and nivolumab?
How will you manage a patient with refractory metastatic unclassified RCC with progression on IO/TKI?
How do you mange stage IV RCC with high tumor burden responding to salvage IO + Cabozantinib but with significant drug associated rise in serum creatinine?
Do you offer adjuvant pembrolizumab post metachronous oligometastatic resection of RCC beyond the first year of diagnosis?
How would you treat a young patient with a resected stage III chromophobe RCC?
In metastatic/recurrent clear cell carcinoma with a solitary site of metastasis to the bone when, if ever, do you consider local therapy adequate and hold systemic therapy?
How do you treat clear cell renal cell carcinoma with metastatic recurrence while on adjuvant pembrolizumab?
How would you treat a patient with metastatic sarcomatoid renal cell carcinoma after progression on Nivolumab and Cabozantinib?
Would the recent use of high dose glucocorticoids impact your selection of first-line therapy for patients with intermediate-poor risk metastatic RCC?
